Financial Performance - MannKind Corporation reported a record revenue quarter of $82 million[13] - Tyvaso DPI-related revenue reached $59 million in Q3 2025, a 15% increase from Q3 2024[13, 22] - Afrezza net revenue for Q3 2025 was $18.5 million, up 23% from Q3 2024[32] - FUROSCIX net revenue for Q3 2025 was $19.3 million, a 93% increase from Q3 2024[37] - Total revenue increased by 17% from Q3 2024 to Q3 2025[50] Product & Clinical Development - Afrezza sBLA was accepted for review, potentially becoming the first new insulin for pediatrics in over 100 years[13, 62] - FUROSCIX doses dispensed in Q3 2025 increased by 153% from Q3 2024[34] - The ICoN-1 global Phase 3 study achieved its interim enrollment target ahead of schedule[69] - INFLO Nintedanib DPI Phase 2 study was initiated, with the first patient expected to enroll in Q1 2026[15, 77] Market Opportunity - The addressable opportunity for heart failure (HF) is greater than $10 billion[39]

Core Insights - MannKind Corporation has successfully completed the acquisition of scPharmaceuticals Inc, which is expected to diversify and accelerate its revenue growth, particularly through the innovative therapy FUROSCIX® for edema related to chronic heart failure and chronic kidney disease [1][2] - The acquisition enhances MannKind's commercial and medical capabilities by integrating scPharmaceuticals' experienced team, positioning the company for further growth in cardiometabolic care [2] - MannKind's annualized revenue run rate exceeds $370 million based on Q2 2025 results, supported by its commercial assets including Afrezza®, FUROSCIX®, and V-Go® [1] Acquisition Details - The acquisition was structured as a tender offer at a price of $5.35 per share in cash, plus a non-tradable contingent value right (CVR) for potential milestone payments, totaling up to $6.35 per share [3] - Approximately 73.47% of scPharmaceuticals' outstanding shares were tendered, allowing the transaction to proceed, with scPharmaceuticals becoming a wholly owned subsidiary of MannKind [4] - Following the acquisition, scPharmaceuticals' common stock ceased trading on Nasdaq [5] Strategic Fit and Future Growth - The strategic alignment between MannKind and scPharmaceuticals creates significant growth opportunities by combining MannKind's endocrinology expertise with scPharmaceuticals' cardiovascular capabilities [2] - MannKind aims to expand FUROSCIX's market reach among nephrologists and cardiologists, enhancing its position in chronic heart failure treatment [2] - The company has a late-stage pipeline that includes Inhaled Clofazimine and nintedanib DPI, which supports long-term value creation [2]